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A R T I C L E   I N F O A B S T R A C T 
The ethnic minority groups (EMGs) are perceived to be more prone to medicine-
related problems (MRPs) than the general population in United Kingdom. There is, 
therefore, a need for improved detection and prevention of MRPs in EMGs, such as 
South Asians (SA) and Middle Eastern (ME) populations, to avoid unnecessary GP 
visits and potential hospital admissions. In this cross-sectional study, the data were 
collected in 80 face-to-face semi-structured interviews using Gordon’s MRPs tool 
from seven pharmacies in London. The study involved patients aged over 18 from 
SA/ME origins who were prescribed three or more medicines. Interviews were 
audiotaped, transcribed verbatim and analysed thematically using Gordon’s 
coding frame and Nvivo 10. All issues under each of the main themes were 
explored and compared in an attempt to systematically adapt the Gordon’s MRPs 
tool for SA/ME populations. Some modifications were made to the original 
Gordon’s MRPs questionnaire to capture patients’ views regarding the use of 
medicines and the access to services. This also helped in identifying MRPs specific 
to SA/ME populations and proposing recommendations to address them. This 
included targeted medication use reviews (MURs), and tailored interventions to 
patients’ needs in improving medication use and access to services.   
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INTRODUCTION  
Medicine-related problems (MRPs) can adversely 
affect patients’ health and treatment outcomes 
(Mannheimer et al., 2006; Viktil et al., 2006; Laroche 
et al., 2007). It can be associated with unnecessarily 
consume of the healthcare system resources due to 
subsequent morbidity, mortality and extra general 
practitioner (GP) consultations (Department of 
Health, 2001; Mannheimer et al., 2006; Viktil et al., 
2006; Laroche et al., 2007). Many studies have found 
that patients do not manage their medicines 
effectively and that they may experience a wide 
range of problems (Lip et al., 2002; Lip et al., 2004; 
Gordon et al., 2005; Lawton et al., 2005; Morgan and 
Figueroa-Muñoz, 2005; Gordon et al., 2007; Sidi et 
al., 2009; Opara et al., 2010; Alhomoud et al., 2013). 
The frequency of MRPs in the community, as 
reported in the literature, is between 2.5 - 65% 
(Hannaoui et al., 1996; Lee and Beard, 1997; 
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Westerlund et al., 1999; Gordon et al., 2005; Gordon 
et al., 2007). Ethnic minority groups (EMGs), 
including South Asians (SA) and Middle Easterners 
(ME), may be more vulnerable to MRPs than 
general population. This is due to the fact that 
EMGs in general often have a higher than average 
prevalence of chronic diseases including diabetes, 
cardiovascular and rheumatoid diseases (Sidi et al., 
2009; Opara et al., 2010; Alhomoud et al., 2013). This 
may lead to co-morbidities and multiple drug 
therapies and consequently MRPs.  
Patients from different cultural backgrounds may be 
expected to have their own views, perceptions and 
beliefs which will affect their use of medicines (Van 
Mil et al., 2004; Bailey et al., 2009; Alhomoud et al., 
2013; Ens et al., 2013). In addition, these groups are 
associated with communication and language 
barriers, and different experiences, needs and 
expectations than the wider UK population which 
may also influence their ability to manage their 
medicines effectively (Bailey et al., 2009; Alhomoud 
et al., 2013; Ens et al., 2013). Moreover, it is 
acknowledged in most health care systems that SA 
and ME groups have experienced inequalities in 
health and in accessing healthcare services 
(Alhomoud et al., 2013). Also, evidence suggests 
that medicine-related needs may be poorly met for 
these groups (Alhomoud et al., 2013). 
From 1990 to 2003, 14 MRPs classification systems 
were introduced to identify MRPs but only eight 
stated a clear definition for MRPs (van Mil et al., 
2004). Two classification systems were introduced 
after year 2003 (AbruRuz et al., 2006; Gordon et al., 
2005). Only two classification systems have a 
hierarchical structure that separates problems from 
causes and interventions (AbuRuz et al., 2006; 
PCNE, 2010). In addition, only four classification 
systems have been validated (Westerlund, 2002; 
Gordon et al., 2005; AbuRuz et al., 2006; PCNE, 
2010). From our perspective, a good classification 
system: (1) should have a clear definition of the 
MRPs; (2) it should also be validated and usable in 
practice; (3) it should be structured in a hierarchical 
way, clearly separate cause from problems and 
preferably also have an intervention section. The 
only three classifications that meet the first two 
criteria are PCNE, Gordon, AbuRuz systems. 
Although Gordon et al.’s system has no hierarchical 
structure, it was employed as a guide to classify 
MRPs in the current study. This is because this 
system includes all aspects of MRPs and focuses on 
patients’ perspectives and needs. In addition, this 
system does not only address medicine-related 
problems but also service-related problems that 
many ethnic minority patients are experiencing. 
Finally, PCNE and AbuRuz systems do not include 
patients’ opinions or perceptions in the classification 
process because they believed that patients’ therapy 
expectations and goals are the same as the 
professionals’, which may not be true for all 
patients.   
Although EMGs may be more prone to MRPs than 
general population, none of the previous tools have 
been used to identify MRPs in these groups. In 
addition, only a small number of instruments have 
focused on patients’ views, beliefs and experiences 
(Gordon et al., 2005; Lawton et al., 2005; Morgan 
and Figueroa-Muñoz, 2005) as the majority of tools 
used to identify MRPs have been from healthcare 
professionals’ (HCPs) perspectives (Van Mil et al., 
2004). Thus, there is a need for improved detection 
and prevention of MRPs in SA and ME groups in 
the primary care, before unnecessary hospital 
admission or a GP visit is required. Thus, the 
objective of this study was to select an existing 
validated tool that can be employed to identify 
MRPs from patients’ perspectives and experiences 
and to make recommendations for the tool to be 
valuable for use in SA and ME populations. 
MATERIALS AND METHODS 
MRPs tool selection 
The tool selected was one which: (1) has a broad 
definition of MRPs ranging from prescribing errors 
through to obtaining supplies, monitoring for 
appropriateness and patients’ behaviours which 
influence their use, (2) is valid, reliable, applicable 
and practical, (3) considers patients’ perspectives, 
experiences and needs. The Gordons’ MRPs 
questionnaire is a short practical tool which 
identifies patients who are experiencing MRPs from 
their perspectives and experiences by obtaining 
systematic information and detailed explanation 
and clarification (Gordon et al., 2005; Gordon et al., 
2007; Sidi et al., 2009; Opara et al., 2010). It employs 
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a broad definition of MRPs, ‘any problem 
experienced by a patient that may impact on their 
ability to manage or take their medicines 
effectively’, to detect a wide range of problems 
(Gordon et al., 2005; Gordon et al., 2007; Sidi et al., 
2009; Opara et al., 2010). It examines in detail the 
problems arising from the patients’ use of medicines 
and health services which may ultimately influence 
patients’ ability to manage their medicines 
effectively. It seeks to explore factors and events 
leading to MRPs from patient’s perspective. The 
tool has shown to be valid and able to correctly 
distinguish between patients with at least one MRP 
and those identified with no MRPs (for 83% of the 
cases) (Gordon et al., 2005). This tool is also reliable 
and the interrater agreement was reported to range 
from 99% to 100% (Gordon et al., 2005). The 
previous tools that have been used to investigate 
medicine-related problems are discussed in the 
‘Introduction’ part. 
The MRPs original screening tool is divided into 
five sections which involve questions regarding 
patients’ medicines, the illnesses for which they take 
their medicines, medications use, service access and 
background information on participants (Gordon et 
al., 2005):  
Section 1 (About your medicines) 
Participants were asked in this section to recall the 
names, doses, dosing frequencies and purposes for 
which they used their prescribed and non-
prescribed medicines. The question aimed at 
obtaining information on what patients were taking 
to gain insight into patients’ knowledge of their 
medicines and to provide a basis for subsequent 
questions. This was cross-checked with pharmacy 
records. This also provided data to indicate any 
potential duplication of medicines, drug-drug 
interaction, lack of information on medicines, 
under-dose, over-dose and problems with non-
prescription medicines. Participants were 
afterwards asked to report if they received help 
with their medicines to describe the nature of the 
help received. The questions asked under each 
section in MRPs tool are presented in Table 1. 
Section 2 (About the illnesses for which you take your 
medicines)  
This section illustrates the number of hospital 
admissions including accident and emergency, and 
consultations as an outpatient or with private 
healthcare professionals in the past five years. It 
highlights differences in service use between these 
groups. It may reflect perceived access to care, and 
therefore it may reflect people finding out more 
about their medicines.  
Section 3 (More about your medicine) 
This section measures self-reporting non-
compliance with prescription medicines and 
demonstrates the nature and frequency of patients’ 
non-compliance. Information was collected in this 
section on participants’ perspectives of their 
medicine-taking behaviour.  
Section 4 (About you GP surgery and pharmacy visits) 
This section gives details relating to contacts with, 
and consultations at, the pharmacy and surgery. 
Participants were asked about the frequency of their 
consultations at the GP surgery (with a GP or 
practice nurse). They were asked in this section to 
report how often they obtained their repeat 
prescriptions. Their purposes for consulting the 
pharmacist and a question on whether they have 
ever run out of supplies of medicines were also 
included. A final question in this section was about 
patients’ sources of information on medicines and 
illnesses. At the end of the questionnaire, 
participants were given the opportunity to add 
additional comment on medicine- or service-related 
issues that were not covered during the interview. 
The following problems emerge at this stage: lack of 
information or discussion, problems with repeat 
prescription, problems with interface, monitoring 
and review, and GP surgery and pharmacy service 
problems.  
Section 5 (About yourself)  
In the original tool, this section includes questions 
on characteristics of participants (e.g., age, gender, 
country of birth, ethnic group, and whether or not 
they live alone) to describe population and not to 
identify MRPs.  
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Study setting, sampling and recruitment 
Eighty face-to-face semi-structured cross-sectional 
interview study was conducted in seven pharmacies 
in the following areas of London: Camden, Brent, 
Harrow and Westminster. This was undertaken to 
examine whether Gordon’s MRPs tool that was 
used in this study is able to identify MRPs in SA 
and ME groups and to capture socio-cultural 
influences on medicines use and service access in 
order to make recommendations for the tool to be 
valuable for use in SA and ME populations. Patients 
were from SA and ME origins, aged over 18 and 
prescribed three or more regular medicines.  
The reason behind focusing on the SA group in the 
present study was because people from the Indian 
subcontinent tend to perceive themselves as less 
healthy than those in the general UK population 
(ONS, 2011; Alhomoud et al., 2015). In addition, 
South Asians now represent one of the UK’s largest 
minority ethnic grouping (ONS, 2011). The Middle 
Eastern group was selected in the current study 
because the percentage of immigration to the UK 
among this group is expected to increase due to 
political instability in the Middle East.  In addition, 
there has been little research which specifically 
examines medicine-related problems in South Asian 
and Middle Eastern populations (Alhomoud et al., 
2015). 
Patients were identified when presenting with a 
prescription in the pharmacy. Data collection 
continued to data-saturation, until the emergence of 
no new issues. The data were collected from May 
2011 to October 2011. The full details on 
recruitment, data collection, translation of the 
questionnaire and transcripts, and quality 
assurance, are described elsewhere (Alhomoud et 
al., 2015).  
Ethical approval was obtained from London City 
and East Research Ethics Committee. A patient 
information sheet was provided to all eligible 
participants who wished to take part. Informed 
written consent was obtained prior to commencing 
the interviews. The patients were reminded that 
they could withdraw from the study at any time 
without providing a reason. The interview was 
audio-recorded for verbatim transcription with the 
participant’s authorization. For participants who 
declined to have an audio-recorded interview, only 
researcher field notes were taken. 
If a significant problem was identified in the course 
of the research, the patients were advised and 
encouraged by the researcher to consult their 
pharmacist or general practitioner (GP), or 
alternatively, if they preferred and with their 
permission and consent, the researcher spoke to the 
community pharmacist on their behalf. Then it was 
the responsibility of the community pharmacist to 
inform the patients’ GP. In the event that the 
patients did not want to inform their GP, then this 
matter was handled by the community pharmacists 
through their normal clinical practice (i.e., it was the 
clinical judgment of the pharmacists in that 
situation regarding whether they wanted to inform 
the patients’ GP when patient safety overrides 
patient confidentiality). Any information that was 
obtained from the patients or pharmacy records was 
be anonymised and treated as confidential 
information and kept in a coded format without the 
name of the patients and locked all the time in a 
designated cabinet for this purpose. Data were 
stored in the University College London (School of 
Pharmacy) computers where all files were password 
protected and only the researcher was allowed to 
access the data.  
Data analysis 
Interviews were guided by the tool and principles of 
qualitative inquiry to achieve our objectives. 
Following each interview, the audio-recorded data 
were transcribed verbatim to enable qualitative 
analysis. The interviews were analyzed thematically 
using Gordon’s coding frame and Nvivo 10 
software. Gordon’s coding frame consists of nine 
main broad categories or codes of MRPs plus a 
number of sub-codes under each main code 
(Alhomoud et al., 2015). When a new problem 
emerged from a participant’s discussion and was 
not included in Gordon’s coding frame, it was 
added to the most appropriate category or code 
(inductively) and all the previous transcripts were 
checked for the relevance of this new code to ensure 
consistency and thoroughness of coding. Any code 
that did not fit into this framework was analyzed 
separately (Alhomoud et al., 2015).  
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Constant comparison techniques, in which all items 
of data are compared with existing codes and sub-
codes were employed. Consequently, the coding 
frame was refined intuitively and moved from 
being largely descriptive to being more responsive 
to emergent and recurrent codes particular to SA 
and ME groups. This stage ended with creating 
seven major codes. One code (i.e., the use of non-
prescription medicines) derived from the Gordon’s 
MRPs coding frame and six new codes comprising 
religious practices and beliefs, extent of family 
support, and travelling abroad – to patient’s 
homeland or to take religious journeys, illiteracy, 
language and communication barriers, lack of 
translated resources, perceptions of healthcare 
providers, and difficulty consulting a doctor of the 
same gender, were found to be particular to SA and 
ME groups (Alhomoud et al., 2015). Through 
thematic coding and analysis of interview 
transcripts, the researcher learned that there was a 
need for a revised version of this tool that can 
identify MRPs that may be specific to SA and ME 
cultures. If these problems are unaddressed, this 
may lead to poor chronic disease management and 
consequently more hospitalization, co-morbidities, 
and wasted resources. 
RESULTS AND DISCUSSION 
Response rates  
Eighty patients (of a total of 100 invited to do so) 
took part in the interview (response rate: 80%). A 
full overview of the participants’ characteristics is 
described elsewhere (Alhomoud et al., 2015).  
Recommendations for the Questionnaire use in 
SA/ME groups 
The principal changes that were made to the 
original Gordon’s MRPs tool included: describing 
the extent of support provided to patients by their 
families in more details (Section 1), providing 
additional prompts to capture the reasons for 
intentional non-compliance that are important to SA 
and ME cultures (Section 3), presenting additional 
prompts to capture the problems that are likely to 
face ME and SA groups in accessing healthcare 
services (Section 4), describing patients’ perception 
of pharmacists’ role, and pharmacy services (Section 
4), and, asking for recommendations or advice from 
patients in order to provide care that is better 
tailored to their needs (Section 4), and, finally 
adding additional patients’ characteristics (Section 
5). The modifications made are described below: 
The extent of family support / help with medicines 
(Section 1) 
Our findings showed that almost half (49%) of 
interview participants reported that they received 
help with medicines. The help received was mainly 
from a family member and was regular (i.e., daily, 
weekly, fortnight or monthly). The extent of support 
revealed by participants was different, ranging from 
undertaking one activity to being responsible for all 
aspects of medicine management. Unlike Gordon et 
al.’s study (2005) which showed that only 19% 
(49/259) of patients reported receiving help with 
medicines, mainly from family members and the 
nature of help was limited to collecting 
prescriptions and dispensed medicines, and 
reminding participants to take medicines. It is worth 
mentioning that Gordon conducted her study 
mainly among White British population (Gordon et 
al., 2005; Gordon et al., 2007). 
Altered medication-taking behaviour was voiced by 
some participants in the present study as a 
consequence of family support. For instance, some 
participants received advice from their relatives to 
stop taking their medicines because their families 
perceived the harm of the medication in general to 
exceed the perceived benefit. Prescription 
medication borrowing and sharing among family 
members was also reported. For example, an Indian 
woman came to the pharmacy to ask for a further 
supply of Omeprazole tablets because she was 
sharing this medicine with her father who was 
already prescribed Ranitidine (dual therapy).  
Our findings indicated that family support is a 
clearly important issue in SA and ME populations. 
These families tend to play a considerable role in all 
aspects of patients’ medicine management which 
sometimes affected patients’ medication-taking 
behaviour and safety. Therefore, in order to identify 
different issues in SAs’ and MEs’ family support 
and to be sure to establish all relevant information, 
additional prompts could be listed under this 
question. Prompts could be as follows: collecting 
prescriptions from GP surgery or medicines from 
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pharmacy, buying non-prescription medicine, 
reminding you to take your medicines, opening 
containers or pulling out tablets, administration, 
understanding or reading information, obtaining 
information, advice on medicines, and other, please 
describe. These prompts will enable us to identify in 
what way these patients have been supported (i.e., 
type of support they receive, by whom and how 
often, what patients say about the help they get and 
how helpful it is). This may be effective in showing 
how carers and participants divide tasks and share 
responsibilities. This may also help in optimizing 
medicine use, improving health outcomes and 
medicine management, and preventing any possible 
MRPs that may occur due to involving carers in 
patients’ care. In particular, adding extra prompts 
may be helpful in identifying what effect family 
support has on patient’s medication-taking 
behaviour (i.e. adherence). No changes have been 
made to section 2 in the tool; therefore, it was not 
mentioned in the ‘results’. 
Medication-taking behaviour (Section 3) 
Various reasons were given by SA and ME patients 
for non-compliance with medications. Some reasons 
were very similar to the ones identified in Gordon’s 
study and other studies but others were reported to 
be specific to SA and ME groups such as religious 
practices and beliefs, cultural and social issues, 
language and communication barriers, etc. These 
reasons that are important to SA and ME 
individuals may not be captured using Gordon’s 
original tool. They were only captured when 
specific prompts about cultural, social and religious 
beliefs were introduced into Gordon’s tool. 
Therefore, it is recommended that, after asking 
closed and open questions in the original tool 
regarding non-compliance, prompts should be 
given to patients to capture reasons that are 
important to SA and ME groups such as Ramadan, 
sharing or lending medicines, advice from family or 
friends, use of OTC or herbal remedies, travelling 
abroad back to their homeland or to take religious 
journeys, others please specify. Patients could also 
be asked to report the medicine and how they had 
changed their prescribed regimen. By using this 
method, more reasons which were reported to be 
particular to SA and ME groups can be examined as 
to why patients adjusted their prescribed regimens.  
About your GP surgery and pharmacy visits (Section 4) 
When participants were asked ‘How well does this 
arrangement at your surgery suit you?’, some 
participants tended to think that this question is 
only related to problems with appointment time, 
waiting time, continuity of care, and length of 
consultation. However, when additional prompts 
were given, participants started to report new 
problems that were particular to SA and ME groups 
such as seeing a GP from the same gender, language 
barrier and absence of an interpreter. Therefore, it is 
highly advised that, after asking the open question 
‘How well does this arrangement at your surgery 
suit you?’, additional prompts might be provided 
such as seeing a GP of the same gender, language 
and interpretation, other please describe.  
The advantage of the open question is to allow 
respondents to express their views fully concerning 
the question, and the advantage of providing 
prompts afterward is to invite respondents to enter 
their thoughts on a specific matter that they may not 
remember or may not consider as a potential issue. 
Providing additional prompts will also enable us to 
capture the problems that are likely to face ME and 
SA participants in particular in accessing healthcare 
services. Careful attention must be taken not to ask 
leading questions when prompting the question.  
It is also recommended that two questions should 
be added to this section; these are:  
Q. How well does the service at your local 
pharmacy works for you? 
Q. Is there anything you think that your doctor, 
pharmacist or nurse could do more to help you 
better manage your medicines? 
The first question will elicit responses describing 
patients’ perceptions of pharmacists’ role and 
pharmacy services to suggest recommendations on 
how pharmacy services should be developed and 
what services need to be implemented in order to 
address the needs of these populations. Such 
responses can describe patients’ perspective of 
pharmacy services and the value that they derive 
from them and show how these services are being 
contextualized with patients’ life world. The second 
question should be added in order to obtain 
recommendations from patients’ perspectives to 
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support them in their use of medicines and access to 
services and to make them more involved in their 
own care. This is important to develop services 
which are better tailored to patients’ needs.   
About yourself (Section 5) 
Additional patient characteristics such as main 
language, ability to speak English, year of arrival in 
the UK, religion, qualification and current 
employment status could be added to this section to 
describe the population further. This may help to 
target the use of the tool and ensure that relevant 
domains and questions are employed. This may also 
enrich the data by including the experiences and 
views of participants from different characteristics. 
Another reason for gathering this additional 
information was because people of different 
characteristics have been found to differ in their 
beliefs about health and medicines, medicine-taking 
behaviour and service use. For example, language 
barrier was voiced to be an issue in accessing 
healthcare services, reading and obtaining 
information by many participants who reported 
having limited English proficiency. A further 
example is that some Muslim participants pointed 
out that while fasting they adapted their use of 
medicines in different ways. Therefore, it is 
recommended that additional patients’ 
characteristics which appear to be important to SA 
and ME groups should be gathered.  
In comparison with Gordon’s MRPs questionnaire, 
the culturally adapted revised version is more 
concise and has direct focus on identifying 
contributory factors to MRPs that were reported to 
be specific to SA and ME groups. Many of these 
factors could be expected to influence patient’s 
safety, adherence, and informed decision-making. 
The revised tool is a practical instrument which can 
be used for the detection of patients with problems 
and provides direction for a more in-depth home 
review if needed.  
In comparison with Medicines Use Reviews (MURs) 
used with patients present in pharmacies the 
adapted version of the tool was able to identify a 
wider range of problems that are reported to be 
specific to SA and ME groups such as religious 
practices and beliefs, use of non-prescription 
medicines, extent of family support, and travelling 
abroad back – to patient’s home land or to take 
religious journeys. Perceptions of healthcare 
providers, difficulty consulting a doctor of the same 
gender, lack of referrals to specialised care, 
language and communication barriers, lack of 
translated resources, illiteracy, lack of involvement 
in the treatment decisions, problems with source, 
delivery, type and timing of information may also 
contribute to the problems. Many of these factors 
could be expected to influence patient’s safety, 
adherence, and informed decision-making 
(Alhomoud et al., 2015). The tool also gave patients 
the opportunity to elaborate on their problems at 
each stage.  
The MURs could be used initially to identify 
patients with problems and who may benefit from a 
more in-depth follow-up using the adapted version 
of the MRPs tool. The adapted version could also be 
utilized during MURs or in audits to improve the 
quality of services and prescribing medicines.  
Identifying ethnicity-specific contributory factors to 
MRPs is important in developing ethnically tailored 
intervention programmes, which have been shown 
to be effective in chronic diseases managements and 
medicine optimization (Bailey et al., 2009, Patel et 
al., 2014; Alhomoud et al., 2015). Thus, 
implementing specific standards, policies and 
practices that comply with patients’ social, cultural 
and linguistic needs should have primacy in the 
NHS.  
The current state of service provision emphasized 
that there is a need to redesign services on an 
assumption of serving multiple users with different 
religious, cultural and social background. For 
instance, including commissioning and placing 
complementary and alternative medicine (CAM) 
providers under the same scrutiny so that they can 
counsel patients in a manner consistent with high-
quality care and evidence-based quality assurance 
process as HCPs (Bailey et al., 2009, Patel et al., 
2014; Alhomoud et al., 2015). In addition, generating 
labels and written instructions in the patient’s 
preferred language, providing instructions using 
graphic symbols for illiterate patients, hiring 
multilingual multilingual staff, using of telephone 
interpreting services such as Language Line and 
using of booked interpreters for consultations could 
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be helpful to ensure effective communication with 
those with lower proficiency in English (Cantarero-
Are´valo et al., 2014; Patel et al., 2014; Alhomoud et 
al., 2015). 
Table 1. The questions asked under each section in the MRPs tool 
Section 1 (About your medicine) 
Q. Can you tell me the names of the prescription medicines you take or use? If you are unable to tell me any 
names, please describe them to me. About each medicine: How many/much and how often do you take/use 
each day? Do you know what you are taking/using this medicine for? For how long have you been 
taking/using this medicine? What other medicines do you take or use? Abut each medicine: What is the 
name of the medicine? What are you using this medicine for? How often do you use this medicine? 
Q. Does anyone help you with your medicines?  Who is this person? How does this person help you? How 
often does this person help you? 
Section 2 (About the illnesses for which you take your medicines) 
Q. About the illnesses for which you take you medicines,  
In the past 5 year have you: 
a. Been admitted to a hospital? Yes/No. 
b. Attended or been taken to A&E/casualty? Yes/No. 
c. Called a GP as an emergency outside surgery hours (i.e., evening or weekends)? Yes/No. 
d. Called a GP or made an appointment as an emergency during surgery hours (i.e., daytime)? Yes/No. 
If yes, please tell me: Which year and month? For what reason? More about this. 
Do you:  
a. Attend hospital as an outpatient? Yes/No. 
b. See any other person privately for your health? Yes/ No. 
If yes, please tell me: Who you see? For what reason? How often? The last time you attended. 
Section 3 (More about your medicine) 
Q. Some people do not always take their medicines according to the instructions, but adjust the dose 
according to what they think they need. Do you do this? Tell me more about this?  
People sometimes forget to take their medicines. Do you do this? Tell me more about this? 
What problems have you experienced with taking your medicines? 
What would you do if you had a problem with taking your medicines? 
Section 4 (About you GP surgery and pharmacy visits) 
Q. How often do you usually consult / see your GP about your illnesses and regular medicines?  
Do you usually consult / see any other person employed at the surgery about your illnesses and regular 
medicines? Yes/ No. If yes, please tell me: who you see? For what reason? How often? 
How well does this arrangement at your surgery suit you? 
When was the last time you consulted / saw your GP or anyone else employed at the surgery about your 
illnesses or regular medicines?   
Q. How do you usually get your prescriptions from your GP surgery? 
How often do you usually get prescriptions for your regular medicines? 
Q. You ever delayed taking your prescription to the pharmacy, after your supply of medicines has run out? 
Yes/No. If yes, tell me more about this. 
Have you ever talked to your pharmacist/chemist about any matters? Yes/No. If yes, please tell me what 
matters. 
Q. What do you think about the information you are given on your medicines?  
Do you have enough information or would you like more? Enough/More. If more, what suggestions do you 
have to improve this? 
Q.  Are there any further comments about your medicines that you would like to add? 
Do you have any questions that you would like to ask me? 
Section 5 (About yourself) 
Q. May I ask how old you are? 
Q. Where is your country of birth? In which year did you come to the UK? Which ethnic group do you 
consider yourself to belong to? 
Q. Do you live alone or with others? 
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Failure to address the UK’s increasingly complex 
and multiple diverse populations will firmly 
establish that being a member of a minority will 
adversely impact on the availability, utility and 
relevance of NHS services and health outcomes. 
Provision of ethnic-specific services, and greater 
awareness of diverse explanations, wants and 
preferences, will help reduce health inequalities and 
reduce the risks associated with mismanagement 
and under-treatment (Bailey et al., 2009, Alhomoud 
et al., 2015).  
Future research to examine the effect of this tool on 
actual changes in medicine-taking behaviour is 
needed. Future studies require also to examine 
whether this tool can be tailored to identify MRPs in 
people from other ethnic backgrounds. Further 
research is also needed in this area to compare the 
prevalence of MRPs between general public and 
other ethnic groups since there is a lack of actual 
evidence in terms of number of MRPs in ethnic 
minority groups in comparison to general public.  
Strengths and limitations 
Strengths: (1) the commonality of the culture and 
language shared by the researcher and participants 
especially those of Arabic origin enhanced the 
success of the interviews; (2) interviews gave an 
insight into the religious, cultural and social norms 
that might facilitate or impede behaviour change in 
order to prevent MRPs; (3) most respondents were 
from deprived communities, whose ﬁrst language 
was not English, and some were illiterate in their 
native language – a population that may be harder 
to reach and at even higher risk of MRPs; (4) in 
pharmacies, participants were sampled at different 
days of the week (and at different times), to avoid 
selection bias and to ensure diversity the sample; (5) 
only one researcher was involved in data collection 
and the interview guide was closely followed to 
reduce any possibility of bias and to eliminate any 
inconsistencies in the procedures. Limitations: (1) 
due to time and resource limitations the sample of 
this research consisted only of SA and ME patients 
who were living in deprived areas; therefore, careful 
attention must be paid before transferring the 
conclusions to non-deprived immigrants and people 
from other ethnic backgrounds; (2) this tool can’t be 
a score based tool as it focuses on patients’ 
experiences, concerns and needs and thus it might 
be difficult to score. 
CONCLUSIONS 
The main responsibility of the pharmacist when 
providing pharmaceutical care is to identify, resolve 
and prevent MRPs. The revised version of MRPs 
tool could have a valuable role in identifying 
patients experiencing MRPs from SA and ME 
origins. It focuses on SA and ME patients’ 
perspectives which may help healthcare 
professionals understand patients’ agendas and 
support them in the use of their medicines. Targeted 
MURs for SA and ME groups should be prioritised. 
The targeted MURs can be developed further to 
focus on all the issues that were reported to be 
specific to SA and ME groups. Tailored 
interventions and pharmaceutical care services to 
patients’ needs and wants may be then required to 
improve medication use and service access. These 
interventions and services should be implemented 
in places that are frequented by EMGs and taught 
by HCPs with the same ethnic background as 
participants. However, the high cost of these 
interventions and services may present limitations 
for their use in everyday practice. Cost-effectiveness 
studies of such interventions are needed, as they 
would provide evidence for the importance of this 
area of research and build the case for the need to 
direct health resources at decreasing medicine-
related problems. 
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